Introduction During the last decade, antiretroviral (ARV) combination therapy has dramatically reduced the mortality of HIV-infected individuals in the countries where these treatments are available. 1,2 Due to the substantially expanded life expectancy and the long-term use of antiretroviral therapy (ART), complications of these highly successful treatment strategies has gained much more attention. The two main complications today associated with antiretroviral therapy are the HIV-associated lipodystrophy and metabolic alterations affecting the lipid and glucose metabolism, which are often but not necessarily found to be associated (see Table 1).
Table 1: Preliminary Classification of Symptoms of the HIV-associated Lipodystrophy Syndrome
Clinical Features and Diagnosis
For the affected patient, the most unpleasant adverse event of antiretroviral therapy is the change in body fat called HIVassociated lipodystrophy. The changes in adipose tissue, peripheral subcutaneous fat loss, visceral or dorsocervical fat accumulation or enlargement of the breast have a marked social and psychological impact and can be perceived as disfiguring and stigmatising (see Figures 1, 2a and 2b). Despite more than 10 years of previous experience with antiretroviral therapy, changes in body fat, as distinct from wasting, were only first reported in 1997. 3,4,5 Overall the prevalence has been reported as high as 80% in antiretroviral-experienced patients.
Figure 1: Facial lipoatrophy characterised by sunken cheeks and hollow temples due to buccal and subcutaneous fat loss
- F J Pallela, Jr, K M Delaney, A C Moorman, M O Loveless, J Fuhrer, G A Statten, D J Aschman and S D Holberg, â€śDeclining Morbidity and Mortality Among Patients with Advanced Human Immunodeficiency Virus Infectionâ€ť, N. Engl. J. Med., 338 (1998), pp. 853â€“861.
- B Gazzard, â€śDevelopment of Antiretroviral Therapies in the Treatment of HIVâ€ť, Business Briefing: Long-term Healthcare Strategies 2003, Business Briefings Ltd: London, July 2003, pp. 62â€“66.
- A Carr, K Samaras, S Burton, M Law, J Freund, D J Chisholm and D A Cooper, â€śA Syndrome of Peripheral Lipodystrophy and Insulin Resistance Due to HIV Protease Inhibitorsâ€ť, AIDS, 12 (1998) 7, pp. F51â€“F58.
- R L Hengel, N B Watts and J L Lennox, â€śBenign Symmetric Lipomatosis Associated with Protease Inhibitorsâ€ť, Lancet, 350 (1997), p. 1,596.
- J C Lo, K Mulligan, V W Tai, et al. â€śâ€Buffalo Humpâ€™ in Men with HIV Infectionâ€ť, ibid., 35 (1998) 1, pp. 867â€“870.
- HIV Lipodystrophy Case Definition Study Group, â€śAn Objective Case Definition of Lipodystrophy in HIVinfected Adults: A Case-control Studyâ€ť, ibid., 361 (2003), pp. 726â€“735.
- A Carr, K Samaras, A Thorisdottir, G R Kaufmann, D J Chisholm and D A Cooper, â€śDiagnosis, Prediction and Natural Course of HIV-1 Protease-inhibitor-associated Lipodystrophy, Hyperlipidaemia and Diabetes Mellitus: A Cohort Studyâ€ť, ibid., 353 (1999), pp. 2,093â€“2,099.
- S A Mallal, M John, C B Moore, et al., â€śContribution of Nucleosides Analogue Reverse Transcriptase Inhibitors to Subcutaneous Fat Wasting in Patients with HIV Infectionâ€ť, AIDS, 14 (2000), pp. 1,309â€“1,316.
- M Van Der Valk, E H Gisolf, P Reiss, et al., â€śIncreased Risk of Lipodystrophy when Nucleoside Analogue Reverse Transcriptase Inhibitors are Included with Protease Inhibitors in the Treatment of HIV-1 Infectionâ€ť, ibid., 15 (2001), pp. 847â€“855.
- T Saint-Marc , M Partisani, I Poizot-Martin, et al., â€śFat Distribution Evaluated by Computed Tomography and Metabolic Abnormalities in Patients Undergoing Antiretroviral Therapy: Preliminary Results of the LIPOCO Studyâ€ť, ibid., 14 (2000), pp. 37â€“49.
- J P Bastard, M Caron, H Vidal, et al., â€śAssociation Between Altered Expression of Adipogenic Factor SREBP1 in Lipoatrophic Adipose Tissue from HIV-1-infected Patients and Abnormal Adipocyte Differentiation and Insulin Resistanceâ€ť, Lancet, 359 (2002), pp. 1,026â€“1,031.
- E Negredo, R Paredes, A Bonjoch, A Tuldra, et al., â€śBenefit of Switching from a Protease Inhibitor to Nevirapine in PI-experienced Patients Suffering Acquired HIV-related Lipodystrophy Syndrome: Interim Analysis at 3 Months Follow-upâ€ť, Antiviral Therapy, 4 (1999) Suppl. 3, pp. 23â€“28.
- E MartĂnez, I Conget, L Lozano, R Casamitjana and J Gatell, â€śReversion of Lipodystrophy After Switching from HIV-1 Protease Inhibitors to Nevirapineâ€ť, AIDS, 13 (1999), pp. 805â€“810.
- T Saint-Marc and J L Touraine, â€śReversibility of Peripheral Fat Wasting (Lipoatrophy) on Stopping Stavudine Therapyâ€ť, ibid., Suppl. 2, p. 45 [abstract 024].
- A Carr, C Workman, D E Smith, J Hoy, J Hudson, N Doong, A Martin, J Amin, M Law and D A Cooper, â€śAbacavir Substitution for Nucleoside Analogs in Patients with HIV Lipoatrophy: A Randomized Trialâ€ť, JAMA, 288 (2002), pp. 207â€“215.
- P Amard, T Saint-Marc and P Katz, â€śThe Effects of Polylactic Acid as Therapy for Lipoatrophy of the Faceâ€ť, Antiviral Therapy, 5 (2000) Suppl. 5, p. 79.
- S Ponce de Leon, M Iglesias, J Ceballos and Zeichner L Ostrosky, â€śLiposuction for Protease Inhibitor-associated Lipodystrophyâ€ť, Lancet, 353 (1999), p. 1,244.
- G W Wolfort, C L Cetrulo and D L Nevarre, â€śSuction-assisted Lipectomy for Lipodystrophy Syndromes Attributed to HIV-protease Inhibitor Useâ€ť, Plastic and Reconstructive Surgery, 6 (1999), pp. 1,814â€“1,819.
- R Roubenoff, L Weiss, A McDermott, T Heflin, G J Cloutier, M Wood and S Gorbach, â€śA Pilot Study of Exercise Training to Reduce Trunk Fat in Adults with HIV-associated fat Redistributionâ€ť, AIDS, 13 (1999), pp. 1,373â€“1,375.
- C Wanke, J Gerrior, J Kantaros, E Coakley and M Albrecht, â€śRecombinant Human Growth Hormone Improves the Fat Redistribution Syndrome (Lipodystrophy) in Patients with HIVâ€ť, ibid., pp. 2,099â€“2,103.
- R Torres, K W Unger, J A Cadman and J Y Kassous, â€śRecombinant Human Growth Hormone Improves Truncal Adiposity and â€Buffalo Humpsâ€™ in HIV-positive Patients on HAARTâ€ť, ibid., pp. 2,479â€“2,481.
- S Mauss, E Wolf and H Jaeger, â€śReversal of Protease Inhibitor-related Visceral Abdominal Fat Accumulation with Recombinant Human Growth Hormoneâ€ť, Ann. Intern. Med., 131 (1999), pp. 313â€“314.
- T Saint-Marc and J L Touraine, â€śEffects of Metformin on Insulin Resistance and Central Adiposity in Patients Receiving Effective Protease Inhibitor Therapyâ€ť, AIDS, 8 (1999), pp. 1,000â€“1,003.
- C Hadigan, C Corcoran, N Basgoz, et al., â€śMetformin in the Treatment of HIV Lipodystrophy Syndromeâ€ť, JAMA, 284 (2000), pp. 472â€“477.
- E MartĂnez, et al., â€śTreatment of Metabolic and Morphologic Complications with Metformin or Gemfibrozilâ€ť, 9th CROI 2002 [abstract 701-T].
- E Sutinen, et al., â€śA Randomized, Double-blind, Placebo-controlled Study of Rosiglitazone in Patients with HIV Lipodystrophyâ€ť, ibid., [abstract LB13].
- C Hadigan, et al., â€śA Randomized, Double-blind, Placebo-controlled Study of Rosiglitazone in Patients with HIV Lipodystrophy: 5th International Workshop on Lipodystrophy and Adverse Drug Reactions 2003â€ť, Antiviral Therapy, Suppl., [abstract 12].
- F D Goebel and R Walli, â€śART-associated Insulin Resistance: Frequency, Potential Causes and Possible Therapeutic Interventions: 1st International Workshop on Adverse Drug Reactions and Lipodystrophy, San Diego 1999â€ť, ibid., 4 (1999) Suppl. 2, p. 13 [abstract 005].
- R K Walli, G M Michl, J R Bogner and F D Goebel, â€śImprovement of HAART-associated Insulin Resistance and Dyslipidemia After Replacement of Protease Inhibitors with Abacavirâ€ť, Eur. J. Med. Res., 6 (2001), pp. 413â€“421.
- K E Yarasheski, P Tebas, S Claxton, et al., â€śHIV-protease Inhibitor Switch to Nevirapine Improves Insulin Tolerance But Does Not Correct Adipose Tissue Maldistributionâ€ť, Antiviral Therapy, 5 (2000) Suppl. 5, p. 78.
- S Mauss, E Wolf and H Jaeger, â€śImpaired Glucose Tolerance in Patients Receiving and Those Not Receiving Protease Inhibitorsâ€ť, Ann. Intern. Med., 130 (1999a), pp. 162â€“163.
- C Grunfeld, M Pang, W Doerrler, J K Shigenaga, P Jensen and K R Feingold, â€śLipids, Lipoproteins, Triglyceride Clearance and Cytokines in Human Immunodeficiency Virus Infection and the Acquired Immunodeficiency Syndromeâ€ť, J. Clin. Endocrinol. Metab., 74 (1992) 5, pp. 1,045â€“1,052.
- D E Sellmeyer and C Grunfeld, â€śEndocrine and Metabolic Disturbance in Human Immunodeficiency Virus Infection and the Acquired Immune Deficiency Syndromeâ€ť, Endocr. Rev., 17 (1996), pp. 518â€“532.
- D Mildvan, S G Machado, I Wilets and S E Grossberg, â€śEndogenous Interferon and Triglyceride Concentrations to Assess Response to Zidovudine in AIDS and Advanced AIDS-related Complexâ€ť, Lancet, 339 (1992), pp. 453â€“456.
- J Constans, J M Marchand, C Conri, E Peuchant, M Seigneur, P Rispal, C Lasseur, J L Pellegrin and B Leng, â€śAsymptomic Atherosclerosis in HIV-positive Patients: A Case-control Ultrasound Studyâ€ť, Ann. Med., 27 (1995) 6, pp. 683â€“685.
- C Leport, M Saves, P Ducimetiere, et al., â€śCoronary Heart Disease Risk (CHD) in French HIV-infected Men Started on a Protease Inhibitor (PI)-containing Regimen Compared to the General Populationâ€ť, 9th CROI 2002 [abstract 697-T].
- M Saves, F Raffi, J Capeau, et al., â€śFactors Related to Lipodystrophy and Metabolic Alterations in Patients with Human Immunodeficiency Virus Infection Receiving Highly Active Antiretroviral Therapyâ€ť, Clin. Infect. Dis., 34 (2002) 10, pp. 1,396â€“1,405.
- S A Bozzette, C F Ake, H K Tam, et al., â€śCardiovascular and Cerebrovascular Events in Patients Treated for Human Immunodeficiency Virus Infectionâ€ť, N. Engl. J. Med., 348 (2003) 8, pp. 702â€“710.
- D Periard, A Telenti, P Sudre, et al., â€śAtherogenic Dyslipidemia in HIV-infected Individuals Treated with Protease Inhibitorsâ€ť, The Swiss HIV Cohort Study, Circulation, 100 (1999) 7, pp. 700â€“705.
- I Sanne, P Piliero, K Squires, et al., â€śResult of Phase 2 Clinical Trial at 48 Weeks (AI424-007): A Dose-rangir Safety and Efficacy Comparative Trial of Atazanavir at Three Doses in Combination with Didanosine and Stavudine on Antiretroviral-naĂŻve Subjectsâ€ť, JAIDS, 32 (2003) 1, pp. 18â€“29.
- M Van Der Valk, J J P Kastelein, R L Murphy, et al., â€śRise in HDL Cholesterol Associated with Nevirapinecontaining Antiretroviral Therapy in HIV-1-infected Patients is Sustained over 96 weeks of Treatmentâ€ť, 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Athens, Greece: 23â€“26 Oct.2001.
- S Staszewski, XIV World AIDS Conference, Barcelona, Spain: 7â€“12 July 2002, [abstract LbOr17].
- M Schmitz, G M Michl, R Walli, et al., â€śAlterations of Apolipoprotein Metabolism in HIV-infected Patients with Antiretroviral Combination Therapyâ€ť, J. Acquir. Immun. Defic. Syndr., 26 (3), pp. 225â€“235.
- P Domingo, X Matias-Guini, R M Pujol, E Francia, E Lagarda, M A Sambeat and G VĂˇzquez, â€śSubcutaneous Adipocyte Apoptosis in HIV-1 Protease Inhibitor-associated Lipodystrophyâ€ť, AIDS, 13 (1999), pp. 2,261â€“2,267.
- S Mauss, J Stechel, R Willers, et al., â€śDifferentiating Hyperlipidamia Associated with Antiretroviral Therapyâ€ť, AIDS, 17 (2003), pp. 189â€“194.
- S Badiou, C M De Boever, A M Dupuy, et al., â€śSmall Dense LDL and Atherogenoc Lipid Profile in HIVpositive Adults: Influence of Lopinavir/Ritonavir-containing Regimenâ€ť, ibid., pp. 772â€“774.
- P Maggi, G Serio, G Epifani, et al., â€śPremature Lesions of the Carotid Vessels in HIV-1-infected Patients Treated with Protease Inhibitorsâ€ť, ibid., 14 (2000) 16, pp. F123â€“128.
- E Seminari, A Pan, G Voltini, et al., â€śAssessment of Atherosclerosis Using Carotid Ultrasosnography in a Cohort of HIV-positive Patients Treated with Protease Inhibitorsâ€ť, Atherosclerosis, 2 (2002) 2, pp. 433â€“438.
- M Depairon, S Chessex, P Sudre, et al., â€śPremature Atherosclerosis in HIV-infected Individuals â€“ Focus on Protease Inhibitor Therapyâ€ť, AIDS, 15 (2001) 3, pp. 329â€“334.
- P Mercie, R Thiebaut, V Lavignolle, et al., â€śEvaluation of Cardiovascular Risk factors in HIV-1 Infected Patients Using Carotid Intima-media Thickness Measurementâ€ť, Ann. Med., 34 (2002) 1, pp. 55â€“63.
- S D Holmberg, A C Moormann, J M Williamson, et al., â€śProtease Inhibitors and Cardiovascular Outcomes in Patients with HIV-1â€ť, Lancet, 360 (2002), pp. 1,747â€“1,748.
- N Friis-MĂ¸ller, R Weber, A D Arminio, et al., â€śExposure to HAART is Associated with an Increased Risk of Myocardial Infarction: The D:A:D Studyâ€ť, 10th CROI 2003 [abstract 130].
- D Klein, L B Hurley, C P Quesenberry, Jr, et al., â€śDo Protease Inhibitors Increase the Risk for Coronary Heart Disease in Patients with HIV-1 Infection?â€ť, J. Acquir. Immun. Defic. Syndr., 30 (2002) 5, pp. 471â€“477.
- J Miller, D Brown, J Amin, et al., â€śA Randomized, Double-blind Study of Gemfibrozil for the Treatment of Protease Inhibitor-associated Hypertriglyceridaemiaâ€ť, AIDS, 16 (2002) 16, pp. 2,195â€“2,200.
- G Moyle, C Baldwin and M Phillpot, â€śManaging Metabolic Disturbances and Lipodystrophy: Diet, Exercise and Smoking Adviceâ€ť, AIDS Read., 12 (2001), pp. 589â€“592.
- F Baldini, S di Giambenedetto, Cingolani, et al., â€śEfficacy and Tolerability of Pravastatin for the Treatment of HIV-1 Protease Inhibitor-associated Hyperlipidaemia: A Pilot Studyâ€ť, AIDS, 14 (2000) 11, pp. 1,660â€“1,662.
- K Henry, H Melroe, J Huebesch, et al., â€śAtorvastatin and Gemfibrozil for Protease-inhibitor-related Lipid Abnormalitiesâ€ť, Lancet, 352 (1998a), pp. 1,031â€“1,032.
- F Visnegarwala, P Sajja, M C Rodriguez-Barraddas, et al., â€śInconsistent Effects of Lipid-lowering Drugs in the Management of HIV-associated Dyslipidemiasâ€ť 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Athens, Greece: 23â€“26 Oct. 2001 [abstract 30].
- C M Mastroianni, G dâ€™Ettorre, G Forcina, et al., â€śRhabdomyolysis After Cervivastatin-gemfibrozil Therapy in an HIV-infected Patient with Protease Inhibitor-related Hyperlipidemiaâ€ť, AIDS,15 (2001) 6, pp. 820â€“821.
- C J Fichtenbaum, J G Gerber, S L Rosenkranz, et al., â€śPharmacokinetic Interactions Between Protease Inhibitors and Statins in HIV Seronegative Volunteers: ACTG Study A5047â€ť, ibid., 16 (2002) 4, pp. 569â€“577.
- G J Moyle, N E Buss and B G Gazzard, â€śPravastatin 40-mg qd Does Not Alter Protease Inhibitor (PI) Exposure or Virological Efficacy over 24 Weeks Therapyâ€ť, 9th CROI 2002 [abstract 446-W].